The longitudinal study of CD200 expression using iPSC-derived DAn and of CD200R1 expression in microglia-like cells derived from peripheral blood monocytes from PD patients represent promising tools that may help to understand the involvement of the CD200-CD200R1 system in the development of PD as well as its potential as a therapeutic target. This evidence concerns the gene CD200 and Parkinson disease.